Quest Diagnostics Inc vs HF Sinclair Corporation Common Stock — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while HF Sinclair Corporation Common Stock trades at $120.83 (market cap $21.46B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and HF Sinclair Corporation Common Stock pays the higher dividend (1.74%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and HF Sinclair Corporation Common Stock for 0 Days on average.
| DGX | DINO | |
|---|---|---|
Market Cap | $25.48B | $21.46B |
Volume | 941,866 | 2,430,580 |
Sector | Health | Energy |
52-Week High | $247.45 | $120.72 |
52-Week Low | $173.49 | $45.88 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $31.23B | $22.44B |
Dividend Yield | 1.49% | 1.74% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →HF Sinclair refines and markets petroleum products, including gasoline, diesel, and jet fuel. It also operates logistics and renewable fuels businesses.
Read more on DINO →